Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation

https://doi.org/10.14412/2074-2711-2017-3-98-104

Full Text:

Abstract

Many antiepileptic drugs (AEDs) have a short half-life (T1/2) with a wide fluctuation from peak to trough blood concentrations. According to this pharmacokinetic profile, there may be both adverse events (AEs) due to the increase in a blood drug concentrations and seizures as a result of its fall, which ultimately lowers patient adherence to therapy.
Pharmaceutical technologies ensuring a delayed release of the active ingredient can make the concentration of a drug more stable and therefore reduce the frequency and severity of AEs, enhance the efficiency of therapy, compliance, and retention of the patient on AEDs. The emergence of a new sustained-release levetiracetam formulation in neurologists' practice greatly enhances the possibilities of epilepsy therapy.

About the Author

P. N. Vlasov
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia; Moscow Regional Research Institute of Obstetrics and Gynecology
Russian Federation

Department of Nervous System Diseases, Faculty of General Medicine
20, Delegatskaya St., Build. 1, Moscow 127473;

Department of Obstetric Physiology
22a, Pokrovka St., Moscow 101000



References

1. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989 Jun 9;261(22):3273-7.

2. Авакян ГН. Отечественная эпилептология: проблемы и возможные пути развития. Эпилептология в системе нейронаук. Сборник материалов. Санкт-Петербург; 2015. С. 4-5. [Avakyan GN. Otechestvennaya epileptologiya: problemy i vozmozhnye puti razvitiya. Epileptologiya v sisteme neironauk. Sbornik materialov [Domestic epileptology: problems and possible ways of development. Epileptology in the system of neurosciences. The collection of materials]. Saint-Petersburg; 2015. P. 4-5.]

3. Карлов ВА, Гехт АБ, Гузева ВИ и др. Алгоритмы моно- и политерапии в клинической эпилептологии. Часть 2. Особенности лечения отдельных групп пациентов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;(7):120-9. [Karlov VA, Gekht AB, Guzeva VI, et al. Algorithms for mono – and polytherapy in clinical epileptology. Part 2. Features of treatment of individual groups of patients. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;(7):120-9. (In Russ.)].

4. Карлов ВА, Гехт АБ, Гузева ВИ и др. Алгоритмы моно- и политерапии в клинической эпилептологии. Часть 1. Общие принципы выбора фармакотерапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;(6):109-14. [Karlov VA, Gekht AB, Guzeva VI, et al. Algorithms for mono – and polytherapy in clinical epileptology. Part 1. General principles for selection of pharmacotherapy. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2016;(6):109-14. (In Russ.)].

5. Карлов ВА. Эпилепсия у детей и взрослых, женщин и мужчин. Москва: Медицина; 2010. 720 с. [Karlov VA. Epilepsiya u detei i vzroslykh, zhenshchin i muzhchin [Epilepsy in children and adults, women and men]. Moscow: Meditsina; 2010. 720 p.]

6. Власов ПН, Орехова НВ, Антонюк МВ и др. Эффективность и безопасность препаратов вальпроевой кислоты с контролируемым высвобождением активного вещества у взрослых в реальной клинической практике с позиции фармакокинетического и фармакогенетического подхода. Неврология, нейропсихиатрия, психосоматика. 2017; 9(1S): 11-20. [Vlasov PN, Orekhova NV, Antonyuk MV, et al. The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017; 9(1S): 11-20. (In Russ.)]. Doi: 10.14412/2074-2711-2017-1S-11-20

7. Saetre E, Perucca E, Isojarvi J, Gjerstad L; LAM 40089 Study Group. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007 Jul; 48(7):1292-302. Epub 2007 Jun 11.

8. Brodie MJ, Overstall PW, Giogri L. Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res. 1999 Oct;37(1):81-7.

9. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Epilepsy Res. 1999 Oct;37(1):81-7.

10. Справочник Видаль «Лекарственные препараты в России». 2017. 23-е издание. [Spravochnik Vidal' «Lekarstvennye preparaty v Rossii» [Vidal Reference «Drugs in Russia»]. 2017. 23th ed.]

11. Boggs J, DeToledo J. Compliance with once-daily divalproex extended-release tablets (Depakote-ER) versus multiple-daily dose valproic acid capsules (Depakene) in epilepsy. Epilepsia. 2007;48(Suppl 6):340–1.

12. Doughty J, Baker GA, Jacoby A, Lavaud V. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav. 2003 Dec;4(6):710-6.

13. Moore JL. Transitioning from immediaterelease to extended-release carbamazepine capsules: medication preference and increased compliance. Epilepsia. 2005;46(Suppl 8):214.

14. Stocks J, Johnson J, Baroldi P. Patient preference for once-daily treatment with extendedrelease topiramate (SPN-538). Epilepsy Curr. 2012;12(Suppl 1):225.

15. Ficker DM, Privitera M, Krauss G, et al. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology. 2005 Aug 23;65(4):593-5.

16. Steinhoff BJ, Wendling AS. Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages. Epilepsy Res. 2009 Dec;87(2-3):256-9. doi: 10.1016/j.eplepsyres.2009.09.013. Epub 2009 Oct 22.

17. Yu PM, Zhu GX, Wu XY, et al. A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy. Seizure. 2011 Jan;20(1):23-6. doi: 10.1016/j.seizure.2010.09.014. Epub 2010 Oct 14.

18. Pierre-Louis SJ, Brannegan RT, Evans AT. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium. Clin Neurol Neurosurg. 2009 Jun;111(5):437-41. doi: 10.1016/j.clineuro.2008.12.009. Epub 2009 Feb 1.

19. Tompson DJ, Ali I, Oliver-Willwong R, et al. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extendedrelease formulation in subjects with epilepsy (The COMPASS Study). Epilepsia. 2008 Mar;49(3):410-7. Epub 2007 Sep 6.

20. Biton V, Shneker BF, Naritoku D, et al. Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials. Clin Drug Investig. 2013 May;33(5): 359-64. doi: 10.1007/s40261-013-0070-4.

21. Chung S, Ceja H, Gawlowicz J, et al. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study. Epilepsy Res. 2012 Aug;101(1-2):92-102. doi: 10.1016/j.eplepsyres.2012.03.007. Epub 2012 Apr 18.

22. Richy FF, Banerjee S, Brabant Y, Helmers S. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using metaanalytic techniques. Epilepsy Behav. 2009 Oct;16(2):240-5. doi: 10.1016/j.yebeh.2009.07.013. Epub 2009 Aug 20.

23. French JA, Baroldi P, Brittain ST, Johnson JK. Efficacy and safety of extendedrelease oxcarbazepine (Oxtellar XR) as adjunctive therapy in patients with refractory partialonset seizures: a randomized controlled trial. Acta Neurol Scand. 2014 Mar;129(3):143-53. doi: 10.1111/ane.12207. Epub 2013 Dec 21.

24. Leppik IE, Hovinga CA. Extended-release antiepileptic drugs: A comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia. 2013 Jan; 54(1):28-35. doi: 10.1111/epi.12043. Epub 2012 Nov 28.

25. Rouits E, Burton I, Guenole E, et al. Pharmacokinetics of levetiracetam XR 500mg tablets. Epilepsy Res. 2009 Apr;84(2-3):224-31. doi: 10.1016/j.eplepsyres.2009.02.001. Epub 2009 Mar 4.


For citation:


Vlasov P.N. Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation. Neurology, Neuropsychiatry, Psychosomatics. 2017;9(3):98-104. (In Russ.) https://doi.org/10.14412/2074-2711-2017-3-98-104

Views: 122


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)